- Home
- QNTM vs BCLI Comparison
QNTM vs BCLI Comparison
Compare QNTM & BCLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNTM
- BCLI
- Stock Information
- Founded
- QNTM 1998
- BCLI 2000
- Country
- QNTM Canada
- BCLI United States
- Employees
- QNTM N/A
- BCLI N/A
- Industry
- QNTM
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QNTM
- BCLI Health Care
- Exchange
- QNTM NYSE
- BCLI Nasdaq
- Market Cap
- QNTM 8.7M
- BCLI 9.9M
- IPO Year
- QNTM N/A
- BCLI N/A
- Fundamental
- Price
- QNTM $8.04
- BCLI $1.21
- Analyst Decision
- QNTM
- BCLI Strong Buy
- Analyst Count
- QNTM 0
- BCLI 1
- Target Price
- QNTM N/A
- BCLI $30.00
- AVG Volume (30 Days)
- QNTM 1.5M
- BCLI 35.3K
- Earning Date
- QNTM 05-13-2025
- BCLI 03-31-2025
- Dividend Yield
- QNTM N/A
- BCLI N/A
- EPS Growth
- QNTM N/A
- BCLI N/A
- EPS
- QNTM N/A
- BCLI N/A
- Revenue
- QNTM N/A
- BCLI N/A
- Revenue This Year
- QNTM N/A
- BCLI $170.09
- Revenue Next Year
- QNTM N/A
- BCLI N/A
- P/E Ratio
- QNTM N/A
- BCLI N/A
- Revenue Growth
- QNTM N/A
- BCLI N/A
- 52 Week Low
- QNTM $2.70
- BCLI $1.05
- 52 Week High
- QNTM $44.72
- BCLI $11.25
- Technical
- Relative Strength Index (RSI)
- QNTM 60.11
- BCLI 30.68
- Support Level
- QNTM $6.45
- BCLI $1.12
- Resistance Level
- QNTM $12.45
- BCLI $1.59
- Average True Range (ATR)
- QNTM 1.66
- BCLI 0.11
- MACD
- QNTM 0.28
- BCLI -0.02
- Stochastic Oscillator
- QNTM 43.80
- BCLI 17.31
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.